Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.
Retina. 2018 Jun;38(6):1180-1186. doi: 10.1097/IAE.0000000000001668.
To evaluate the incidence of pseudophakic macular edema (PME) in eyes with a history of retinal vein occlusion before cataract surgery and to identify any associated risk factors.
The records of 21,332 eyes that underwent cataract surgery were retrospectively reviewed. Eyes that had retinal vein occlusion preoperatively with no evidence of macular pathology on optical coherence tomography at the time of surgery and no macular edema treatment at least 6 months before surgery were included. Eyes with diabetes or diabetic retinopathy, those with a history of previous intraocular surgery or with intraoperative complications, and those administered glaucoma and nonsteroidal antiinflammatory eye drops were excluded.
Pseudophakic macular edema developed in 31 (27.4%) of 113 eyes within 3 months of cataract surgery. Mean visual acuity for eyes with PME (0.48 logarithm of the minimum angle of resolution [logMAR; 20/60 Snellen equivalent]) at 3 months after surgery was significantly worse than that for eyes without PME (0.28 logMAR; 20/38, P = 0.020). However, there was no significant difference in the visual acuity between the 2 groups 6 months after the surgery. Taking into consideration various baseline factors, a history of previous treatment of macular edema was significantly associated with an increased risk of PME (odds ratio, 11.022; 95% confidence interval, 7.258-17.712; P = 0.009). A higher number of intravitreal injections used to treat macular edema also significantly increased the risk of PME (odds ratio, 1.902; 95% confidence interval, 1.032-4.227; P = 0.031).
Pseudophakic macular edema frequently developed after phacoemulsification cataract surgery in patients with a history of retinal vein occlusion. The risk of PME further increased when the patient had undergone macular edema treatment and had a higher prevalence of intravitreal injection treatment.
评估视网膜静脉阻塞病史患者白内障术前发生后发性白内障黄斑水肿(PME)的发生率,并确定任何相关的危险因素。
回顾性分析了 21332 例接受白内障手术的患者的病历。纳入标准为术前有视网膜静脉阻塞,术中光学相干断层扫描(OCT)未见黄斑病变,且术前至少 6 个月无黄斑水肿治疗史。排除患有糖尿病或糖尿病视网膜病变、既往眼内手术史或术中并发症、接受青光眼和非甾体抗炎滴眼液治疗的患者。
在白内障手术后 3 个月内,31 只(27.4%)眼发生 PME。术后 3 个月时,PME 眼的平均视力(0.48 对数最小角分辨率[logMAR;20/60 斯耐伦等效])明显差于无 PME 眼(0.28 logMAR;20/38,P=0.020)。然而,两组术后 6 个月的视力无显著差异。考虑到各种基线因素,既往黄斑水肿治疗史与 PME 风险增加显著相关(优势比,11.022;95%置信区间,7.258-17.712;P=0.009)。用于治疗黄斑水肿的玻璃体内注射次数越多,PME 的风险也显著增加(优势比,1.902;95%置信区间,1.032-4.227;P=0.031)。
视网膜静脉阻塞病史患者白内障超声乳化术后常发生后发性白内障黄斑水肿。当患者接受过黄斑水肿治疗且玻璃体内注射治疗更为普遍时,PME 的风险进一步增加。